Harland Abigail, Liu Xia, Ghirardello Mattia, Galan M Carmen, Perks Claire M, Kurian Kathreena M
Brain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Galan Research Group, School of Chemistry, University of Bristol, Bristol, United Kingdom.
Front Oncol. 2021 Aug 31;11:743814. doi: 10.3389/fonc.2021.743814. eCollection 2021.
Glioma stem-like cells (GSCs) were first described as a population which may in part be resistant to traditional chemotherapeutic therapies and responsible for tumour regrowth. Knowledge of the underlying metabolic complexity governing GSC growth and function may point to potential differences between GSCs and the tumour bulk which could be harnessed clinically. There is an increasing interest in the direct/indirect targeting or reprogramming of GSC metabolism as a potential novel therapeutic approach in the adjuvant or recurrent setting to help overcome resistance which may be mediated by GSCs. In this review we will discuss stem-like models, interaction between metabolism and GSCs, and potential current and future strategies for overcoming GSC resistance.
胶质瘤干细胞（GSCs）最初被描述为一个可能部分对传统化疗有抗性并导致肿瘤复发的细胞群体。了解控制GSC生长和功能的潜在代谢复杂性，可能会揭示GSCs与肿瘤主体之间的潜在差异，从而为临床应用提供依据。作为一种潜在的新型治疗方法，直接/间接靶向或重编程GSC代谢，以克服可能由GSCs介导的耐药性，在辅助治疗或复发性疾病中越来越受到关注。在这篇综述中，我们将讨论干细胞样模型、代谢与GSCs之间的相互作用，以及当前和未来克服GSC耐药性的潜在策略。
